Oral drug for advanced solid tumors including ovarian cancer
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed solid tumor that has spread or come back
- You have tried standard treatments that no longer help, or you cannot take them
- Your cancer is measurable on scans, but during the early dose phase, even non-measurable disease may be okay
- You are in good enough health to be up and about most of the day (ECOG 0–1)
- For some groups: you have high-grade serous ovarian cancer that is resistant to platinum, or you have squamous non-small cell lung cancer after prior treatment
- No untreated or unstable brain metastases, and no recent major surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced solid tumors. It may help if your cancer has not responded to other treatments, and the goal is to see how safe and effective this new approach is.
This trial tests an experimental drug (ATX-898) alone or with other treatments for advanced solid tumors. It aims to see if the drug is safe and works against cancer, and it may be an option if you've already tried standard treatments.
This study tests a new drug called SYS6043, alone or with other treatments, for advanced solid tumors that have not responded to standard therapy. It may offer a new option for patients with certain types of ovarian, fallopian tube, or primary peritoneal cancer.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This early-stage study tests ASKG915, a new treatment, for people with advanced solid cancers that are no longer responding to standard care (or don’t have standard options). If you may qualify, you’d be screened with recent health tests to check safety and eligibility, and then receive the study drug.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
Hear when a new Breast Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.